Overview

Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS)

Status:
Completed

Trial end date:
2009-05-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to learn if decitabine (given at 3 different doses) can help to control Myelodysplastic Syndrome (MDS). The safety of these 3 treatments will also be studied.

Phase:

Phase 2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

Eisai Inc.

Treatments:

Azacitidine
Decitabine